EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Setting higher standards for migraine prevention: A position statement of the International Headache Society

Simona Sacco iD, Messoud Ashina, Hans-Christoph Diener iD, Faraidoon Haghdoost iD, Mi Ji Lee iD, Teshamae S Monteith iD, Bronwyn Jenkins, Mario F P Peres iD, Patricia Pozo-Rosich iD, Raffaele Ornello iD, Francesca Puledda iD, Fumihiko Sakai und 6 weitere

Cephalalgia · 2025-02 · 45 (2)

DOI: 10.1177/03331024251320608 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cephalalgia, online erschienen am 21.02.2025. Verfasst von Simona Sacco und 17 weiteren Autor:innen. Beteiligte Einrichtung: Departiment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy. Hauptthemen laut MEDLINE: Migraine Disorders, Societies, Medical. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Migraine is one of the most prevalent and disabling neurological diseases, significantly affecting quality of life and productivity, as well as contributing to substantial societal costs. Recent innovations, including calcitonin gene-related peptide (CGRP) pathway inhibitors and onabotulinumtoxinA, have transformed migraine prevention by offering high efficacy and excellent tolerability, thus improving adherence. Clinical trials and real-world studies show that significant reductions in migraine frequency and, in some cases, complete migraine freedom is achievable. In this Position Statement, we advocate for raising the standards of migraine prevention by setting ambitious treatment goals aimed at optimal outcomes, such as migraine freedom or very low number of days with migraine or moderate/severe headache. We emphasize the importance of addressing residual migraine burden, highlighting that achieving a ≥50% reduction in monthly migraine days, although often considered a successful response, may not fully restore quality of life. Relying solely on percentage-based improvements can obscure the persisting impact of residual burden. This Position Statement does not want to change the standards for clinical trials but aims primarily at real-world clinical practice and proposes a shift from percentage-based measures of success to absolute goals while on treatment. We outline a framework that categorizes outcomes into four tiers: migraine freedom (no days with migraine or moderate-to-severe headache), optimal control (less than four days with migraine or moderate-to-severe headache), modest control (four to six days with migraine or moderate-to-severe headache) and insufficient control (more than days with migraine or moderate-to-severe headache). Focusing on residual burden while on treatment aims to further improve patient quality of life and drive innovation in preventive therapies and non-pharmacological approaches. By advocating for higher standards, this Position Statement, is not aimed primarily to drive reimbursement policies for migraine preventive treatments, but seeks to inspire clinicians, researchers and policymakers to prioritize ambitious goals in migraine prevention, ultimately enhancing patient outcomes and reducing the broader societal and economic impact of this debilitating condition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersSocieties, MedicalHumansQuality of Life

Stichwörter der Autor:innen

CGRPchronic migrainegepantmigrainemonoclonal antibodiesprevention

Autor:innen und Institutionen

  • Departiment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
  • Department of Neurology, Danish Headache Center, Copenhagen University Hospital, Rigshospitalet, Glostrup, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Department of Neuroepidemiology, Institute for Medical Informatics, Biometry and Epidemiology (IMIBE), Faculty of Medicine, University Duisburg-Essen, Essen Germany.
  • The George Institute for Global Health, University of New South Wales, Sydney, Australia.
  • Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.

ORCID-Profile: Simona Sacco, Hans-Christoph Diener, Faraidoon Haghdoost, Mi Ji Lee, Teshamae S Monteith, Mario F P Peres, Patricia Pozo-Rosich, Raffaele Ornello, Francesca Puledda, Todd J Schwedt, Shuu-Jiun Wang, Fayyaz Ahmed, Cristina Tassorelli

Zitieren

APA

Sacco, S., Ashina, M., Diener, H. C., Haghdoost, F., Lee, M. J., Monteith, T. S., Jenkins, B., Peres, M. F. P., Pozo-Rosich, P., Ornello, R., Puledda, F., Sakai, F., Schwedt, T. J., Terwindt, G., Vaghi, G., Wang, S. J., Ahmed, F., & Tassorelli, C. (2025). Setting higher standards for migraine prevention: A position statement of the International Headache Society. Cephalalgia, 45(2). https://doi.org/10.1177/03331024251320608

Vancouver

Sacco S, Ashina M, Diener HC, Haghdoost F, Lee MJ, Monteith TS, et al. Setting higher standards for migraine prevention: A position statement of the International Headache Society. Cephalalgia. 2025;45(2). doi:10.1177/03331024251320608

BibTeX
@article{Sacco2025,
  author = {Sacco, Simona and Ashina, Messoud and Diener, Hans-Christoph and Haghdoost, Faraidoon and Lee, Mi Ji and Monteith, Teshamae S and Jenkins, Bronwyn and Peres, Mario F P and Pozo-Rosich, Patricia and Ornello, Raffaele and Puledda, Francesca and Sakai, Fumihiko and Schwedt, Todd J and Terwindt, Gisela and Vaghi, Gloria and Wang, Shuu-Jiun and Ahmed, Fayyaz and Tassorelli, Cristina},
  title = {Setting higher standards for migraine prevention: A position statement of the International Headache Society},
  journal = {Cephalalgia},
  year = {2025},
  volume = {45},
  number = {2},
  doi = {10.1177/03331024251320608}
}
Kostenlos starten →